natgillin/translations-raw huggingface dataset:
The CHMP considered that the data suggests that the likely long term protection afforded by Menitorix should not be a cause for concern when used for priming and boosting or for boosting children primed with other MenC conjugate vaccines. 
CHMP je menil, da podatki kažejo, da verjetna dolgotrajna zaščita, ki jo nudi zdravilo Mentorix, ne bi smela biti razlog za skrb pri uporabi za osnovno in poživitveno cepljenje ali samo za poživitveno cepljenje pri otrocih, ki so prejeli osnovni odmerek drugega konjugiranega cepiva proti MenC.
Clinical trials have evaluated the antibody responses at one month after two doses and after completion of a 3-dose primary vaccination course of Menitorix (co-administered with DTPa-HBVIPV or DTPa-IPV vaccines) given at approximately 2, 3, 4 months or 2, 4, 6 months to 814 infants. 
V kliničnih preskušanjih so protitelesni odziv en mesec po prejemu dveh odmerkov cepiva in po dokončanju osnovnega cepljenja s tremi odmerki cepiva Menitorix (sočasno cepljenje s cepivom DTPa-HBV-IPV ali DTPa-IPV) približno v 2., 3., 4. mesecu ali 2., 4., 6 mesecu ovrednotili pri 814 otrocih.
The nurse or doctor will give Menitorix as an injection into the muscle (usually into the thigh muscle but in toddlers the arm muscle can be used) and will make sure that the vaccine is not given into a blood vessel or into the upper layer of the skin. 
Medicinska sestra ali zdravnik bo cepivo vbrizgal v mišico (običajno v mišico stegna, pri starejših otrocih pa lahko tudi v mišico nadlahti).
SmithKline Beecham plc 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom 
SmithKline Beecham plc 980 Great West Road, Brentford, Middlesex TW8 9GS, Velika Britanija
After the first course of vaccinations against Hib and MenC has been completed a booster dose of Hib and MenC should be given, usually at some time in the second year of life. 
Po dokončanem osnovnem cepljenju proti Hib in MenC mora otrok prejeti obnovitveni odmerek cepiva proti Hib in MenC, običajno sočasno v drugem letu življenja.
The new totals are therefore 3293 infants vaccinated with Menitorix either as a primary course or as a booster and 578 infants vaccinated with 1713 doses of closely related Hib-MenC formulations. 
Novi seštevki bolnikov so torej 3.293 dojenčkov, ki so jih cepili z zdravilom Menitorix v obliki osnovnega ali poživitvenega cepljenja, in 578 dojenčkov, ki so jih cepili s 1.713 odmerki zdravil z zelo podobnimi formulacijami Hib-MenC.
Each dose of Menitorix is a single injection of half a millilitre (0.5 ml). 
En odmerek cepiva Menitorix je enkratna injekcija pol mililitra (0,5 ml) cepiva.
Antibody levels have been measured at 18 months after the administration of a booster dose of Menitorix at age 14 Months to subjects who had been primed in infancy with either Menitorix at 2, 4 and 6 months of age or with NeisVac-C at 2, 4 months of age (and a DTPa/Hib containing vaccine at 2, 4, 6 months of age). 
Koncentracija protiteles je bila določena 18 mesecev po cepljenju z obnovitvenim odmerkom cepiva Menitorix pri starosti 14 mesecev pri osebah, ki so bile osnovno cepljene v otroštvu bodisi s cepivom Menitorix v starosti 2, 4 in 6 mesecev ali cepivom NeisVac-C v starosti 2, 4 mesece (in cepivom DTPa/Hib pri starosti 2, 4, 6 mesece).
Menitorix should be given by intramuscular injection only, preferably in the anterolateral thigh region. 
Cepivo Menitorix je treba injicirati intramuskularno, po možnosti v anterolateralni predel stegna.
The vaccine must be reconstituted by adding the entire contents of the pre-filled syringe of solvent to the vial containing the powder. 
Cepivo rekonstituirajte tako, da celotno količino vehikla v napolnjeni injekcijski brizgi dodate viali s praškom.
In a trial of primary vaccination, concomitant administration of an investigational vaccine containing the same amount of conjugated Hib and MenC saccharides as in Menitorix with DTPa-HBV-IPV* and a licensed pneumococcal saccharide conjugated vaccine (the three injections were made into anatomically distant sites) gave similar immune responses to the seven pneumococcal serotypes as achieved in a group that received DTPa-HBV-IPV* concomitantly with Hib (conjugated to tetanus toxoid) and a licensed pneumococcal saccharide conjugated vaccine. 
V preskušanju osnovnega cepljenja je bil pri sočasnem cepljenju s preiskovanim cepivom, ki je vsebovalo enako količino konjugiranih Hib in MenC saharidov, kot cepivo Menitorix, in cepivom DTPa-HBV-IPV* ter uradno potrjenim cepivom s konjugiranim pnevmokoknim saharidom (tri injekcije na anatomsko različna mesta) imunski odziv na sedem serotipov pnevmokokov enak kot v skupini, ki je prejela cepivo DTPa-HBV-IPV* skupaj s cepivom proti Hib (konjugirano na tetanusni toksoid) in uradno potrjeno konjugirano cepivo s pnevmokoknim saharidom.
In two clinical trials (N=578), Menitorix was administered concomitantly with Measles, Mumps, Rubella (MMR) vaccine. 
V dveh kliničnih preskušanjih so osebe (N = 578) cepivo Menitorix prejele skupaj s cepivom proti ošpicam, mumpsu in rdečkam (MMR).
Remember that the first dose of Menitorix should not be given before your child is 2 months of age. 
Otrok prvega odmerka cepiva Menitorix ne sme prejeti, dokler ne dopolni dveh mesecev starosti.
Powder in a vial (type I glass) with a stopper (butyl rubber), 0.5 ml of solvent in a pre-filled syringe (type I glass) with a plunger stopper (butyl rubber) with or without separate needles in the following pack sizes: - pack size of 1 vial of powder plus 1 pre-filled syringe of solvent with 2 separate needles or without needles - pack size of 10 vials of powder plus 10 pre-filled syringes of solvent with 2 separate needles or without needles 
0,5 ml vehikla v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (butilna guma) in s priloženimi injekcijskimi iglami ali brez v naslednjih velikostih pakiranja: - 1 viala s praškom in 1 napolnjena injekcijska brizga z vehiklom, skupaj z 2 priloženima injekcijskima iglama ali brez.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not inject intravenously. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Cepivo ne smete injicirati v žilo.
≥0.15 micrograms/ml ≥1 micrograms/ml 
≥ 0,15 mikrogramov/ml ≥ 1 mikrogram/ml
Like all medicines, Menitorix can cause side effects, although not everybody gets them. 
Kot vsa cepiva ima lahko tudi cepivo Menitorix neželene učinke, ki pa se ne pojavijo pri vseh cepljenih osebah.
• if your child takes medicines or has any treatment which may affect the immune system. 
• če se otrok zdravi ali se je zdravil s katerimkoli zdravilom, ki lahko vpliva na delovanje imunskega sistema, ali ima okužbo z virusom HIV ali katero drugo bolezen, ki lahko zmanjša njegovo odpornost proti okužbam.
Overall, the CHMP considers the safety database to be of adequate size and satisfactory in content, supporting the use of Menitorix for priming in infancy and for boosting children in the second year of life who have been primed with Menitorix or with other Hib and MenC conjugate vaccines. 
V splošnem CHMP meni, da je baza podatkov o varnosti primerne velikosti in zadovoljiva po vsebini ter da podpira uporabo zdravila Menitorix za osnovno cepljenje dojenčkov in poživitveno cepljenje otrok v drugem letu starosti, ki so že prejeli osnovno cepljenje z zdravilom Menitorix ali drugimi konjugiranimi cepivi proti virusu Hib in MenC.
Overall, 92.7% of 177 subjects had SBA-MenC titres of at least 1:8 and 99.4% of the 178 subjects had anti-PRP antibody concentrations of at least 0.15 µg/ml. 
V celoti je titre SBA-MenC vsaj 1:8 imelo 92,7 % od 177 oseb, koncentracijo protiteles anti-PRP vsaj 0,15 µg/ml pa 99,4 % od 178 oseb.
In the group primed with NeisVac-C 115/121 (95%) had SBA-MenC titers of at least 1:8 and 121/122 (99.2%) had anti-PRP antibody concentrations of at least 0.15 µg/ml. 
V skupini, ki je bila osnovno cepljena s cepivom NeisVac-C je titre SBA-MenC vsaj 1:8 imelo 115/121 (95 %) oseb, koncentracijo protiteles anti-PRP vsaj 0,15 µg/ml pa 121/122 (99,2 %).
Acute severe febrile illness. 
Hujše akutno obolenje z zvišano telesno temperaturo.
The vaccine cannot cause Hib and MenC. 
Cepivo ne more povzročiti okužbe s Hib ali MenC.
Although symptoms of meningism such as neck pain/stiffness or photophobia have been reported following administration of other MenC conjugate vaccines, there is no evidence that MenC conjugate vaccines cause meningitis. 
Po dajanju drugih konjugiranih cepiv proti MenC so poročali simptomih meningizma, kot so bolečina v vratu/otrdelost vratu ali fotofobija, vendar pa ni dokazov, da bi konjugirana cepiva proti MenC povzročila meningitis.
When Menitorix was administered as a 3-dose primary vaccination course, a DTPaHBV-IPV* vaccine (N=796) or a DTPa-IPV vaccine* (N=375) was administered concomitantly. 
Med osnovnim cepljenjem s 3 odmerki cepiva so osebe sočasno prejele cepivo DTPa-HBV-IPV* (N = 796) ali cepivo DTPa-IPV* (N = 375).
Powder and solvent for solution for injection White powder and a clear colourless solvent. 
FARMACEVTSKA OBLIKA Prašek in vehikel za raztopino za injiciranje Bel prašek in bister ter brezbarven vehikel.
Psychiatric disorders: very common: irritability uncommon: crying 
Zelo pogosti: razdražljivost Občasni: jok
The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of physical aspect prior to administration. 
Pred cepljenjem morate rekonstituirano cepivo vizualno pregledati glede morebitne prisotnosti kakršnihkoli tujih delcev in/ali neobičajnega fizikalnega videza.
The immune response to the Hib and MenC components of Menitorix was only assessed in primary vaccination clinical studies that employed co-administration with DTPa-IPV* or DTPa-HBV-IPV* vaccines. 
Imunski odziv na komponenti proti Hib in MenC cepiva Menitorix je bil ovrednoten le v kliničnih študijah osnovnega cepljenja, v katerih so osebe sočasno prejele tudi cepivo DTPa-IPV* ali DTPa-HBV-IPV*.
There are no data on concomitant use of Menitorix with whole cell pertussis and oral poliomyelitis vaccines, however, no interference is expected. 
O sočasni uporabi cepiva Menitorix in cepiva proti oslovskemu kašlju s celotno celico ter peroralnega cepiva proti otroški ohromelosti ni podatkov, vendar pa medsebojnega delovanja ne pričakujemo.
10 x 1 dose (0.5 ml) 
10 x 1 odmerek (0,5 ml)
Read the package leaflet before use Shake well before use 
Pred uporabo preberite priloženo navodilo.
Anti-PRP antibodies micrograms/ml micrograms/ml GMC (micrograms/ml rSBA-MenC 
Anti-PRP protitelesa mikrogramov/ml ≥ 1 mikrogram/ml GMC (mikrogrami/ml) rSBA-MenC
In a trial of booster vaccination against Hib and MenC, Menitorix was administered concomitantly (into opposite thighs) with a first dose of combined measles, mumps and rubella (MMR) vaccine. 
V preskušanju obnovitvenega cepljenja proti Hib in MenC, so osebe cepivo Menitorix prejele sočasno (v drugo stegno) s prvim odmerkom kombiniranega cepiva proti ošpicam, mumpsu in rdečkam (MMR).
Hypersensitivity reaction after previous administration of Menitorix. 
Preobčutljivostna reakcija po predhodnem cepljenju s cepivom Menitorix.
No data are available on the use of Menitorix in immunodeficient subjects. 
Podatki o uporabi cepiva Menitorix pri nedonošenčkih niso na voljo.
In various studies with licensed monovalent meningococcal group C conjugate vaccines, concomitant administration with combinations containing diphtheria, tetanus and acellular pertussis components (with or without inactivated polio viruses, hepatitis B surface antigen or Hib conjugate [e.g. DTPaHBV-IPV-Hib*]), has been shown to result in lower serum bactericidal antibody (SBA) geometric mean titres (GMT) compared to separate administrations or to co-administration with whole cell pertussis vaccines. 
V različnih študijah so bili pri cepljenju z uradno potrjenimi monovalentnimi konjugiranimi cepivi proti meningokokom skupine C v kombinaciji s cepivi proti davici, tetanusu in oslovskemu kašlju (acelularno) (z inaktiviranimi poliovirusi, površinskim antigenom virusa hepatitisa B ali Hib konjugatom ali brez [npr. DTPa-HBV-IPV-Hib*]) geometrijski srednji titri (GMT; “geometric mean titres”) baktericidnih protiteles v serumu nižji kot pri ločenem ali sočasnem cepljenju s cepivi proti oslovskemu kašlju s celotno celico, delež oseb s titri SBA vsaj 1:8 pa ni bil manjši.
powder and solvent for solution for injection intramuscular injection 
Prašek in vehikel za raztopino za injiciranje
If you miss an appointment, it is very important that you contact the surgery or clinic and make a new appointment for your child to have the missed dose or doses as soon as possible. 
Če ste na dogovorjeni termin pozabili je zelo pomembno, da se čimprej dogovorite za naslednji termin, da bo otrok čimprej prejel preostale odmerke cepiva.
Based on - the Rapporteur's and Co-Rapporteur's assessment reports, - the Applicant/MAH response to the CHMP questions, - the Scientific discussion within the Committee, 
- ocenjevalnih poročil poročevalca in soporočevalca, - odziva predlagatelja/imetnika dovoljenja za promet z zdravilom na vprašanja odbora CHMP, - znanstvene razprave v Odboru je CHMP priporočil odobritev dovoljenja za promet z zdravilom Menitorix, s popravki v ustreznih delih informacij o zdravilu in z obvezami, ki jih je treba izpolniti.
N= number of subjects with available results %= percentage of subjects with titres equal to or above the cut-off PRP= polyribosylribitol phosphate rSBA-MenC= serum bactericidal antibodies against meningococcal polysaccharide C using rabbit complement 
N = število oseb z razpoložljivimi rezultati %= odstotek oseb s titri, enakimi ali večjimi od mejne vrednosti testa PRP= poliribozilribitol fosfat rSBA-MenC= serumska baktericidna protitelesa proti meningokoknemu polisaharidu C pri uporabi kunčjega komplementa
GENERAL CLASSIFICATION FOR SUPPLY [To be completed nationally] Medicinal product subject to medical prescription. 
[Izpolni država članica] Izdaja zdravila je le na recept.
In the Menitorix primed and boosted group 49/56 (87.5%) of the subjects had SBA-MenC titers of at least 1:8 and 56/56 (100%) had anti-PRP antibody concentrations of at least 0.15 µg/ml. 
V skupini, ki je prejela osnovne in obnovitveni odmerek cepiva Menitorix, je titre SBA-MenC vsaj 1:8 imelo 49/56 (87,5 %) oseb, koncentracijo protiteles anti-PRP vsaj 0,15 µg/ml pa 56/56 (100%).
The reconstituted vaccine is a clear and colourless solution.Inject the entire contents of the vial. 
Rekonstituirano cepivo je bistra in brezbarvna raztopina.
MenC PSC - Neisseria meningitidis serogroup C polysaccharide 
MenC PSC - polisaharid Neisseria meningitidis serološke skupine C
After two doses N=111 
Po dveh odmerkih N = 111
In children who received an acellular pertussis combination vaccine containing Hib in the primary infant immunisation series the Hib booster dose should be given before the age of 2 years. 
Otrok, ki je med osnovnim cepljenjem prejel kombinirano cepivo z acelularno komponento proti oslovskemu kašlju in komponento proti Hib, mora obnovitveni odmerek cepiva proti Hib prejeti pred dopolnjenim drugim letom starosti.
There are no data on the use of Menitorix for one or two doses of the primary vaccination course and other Hib and/or MenC conjugate vaccines for other dose(s). 
Podatki o osnovnem cepljenju z enim ali dvema odmerkoma cepiva Menitorix in odmerkom (odmerki) drugega konjugiranega cepiva proti Hib in/ali MenC niso na voljo.
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and single and repeated dose toxicity studies. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti in toksičnosti pri enkratnem odmerku ter ponavljajočih se odmerkih ne kažejo posebnega tveganja za človeka.
The data support the use of Menitorix for priming in infancy and for boosting in the second year of life and for boosting toddlers who have been primed with Menitorix or with other Hib and MenC conjugate vaccines. 
Podatki podpirajo uporabo zdravila Menitorix za osnovno cepljenje pri dojenčkih in poživitveno cepljenje v drugem letu starosti ter za poživitveno cepljenje majhnih otrok, ki so prejeli osnovni odmerek zdravila Menitorix ali drugih konjugiranih cepiv proti Hib in MenC.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine. 
Pri cepljenju je, tako kot pri vseh cepivih, ki se jih injicira, treba zagotoviti ustrezno obliko zdravljenja in nadzora, ki morata biti v takšnem primeru nemudoma na voljo.
After primary vaccination in infancy, booster doses of Hib and MenC must be administered. 
Po osnovnem cepljenju mora otrok prejeti obnovitveni odmerek cepiva proti Hib in MenC.
Read all of this leaflet carefully before your child starts receiving this vaccine. 
Pred začetkom cepljenja natančno preberite navodilo!
After three doses N=111 
Po treh odmerkih N = 111
PRP= polyribosylribitol phospohate rSBA-MenC= serum bactericidal antibodies against meningococcal polysaccharide C using rabbit complement 
PRP= poliribozilribitol fosfat rSBA-MenC= serumska baktericidna protitelesa proti meningokoknemu polisaharidu C pri uporabi kunčjega komplementa
In clinical trials of primary vaccination series, Menitorix was administered concomitantly (into opposite thighs) with a DTPa-HBV-IPV vaccine. 
V kliničnih preskušanjih osnovnega cepljenja so osebe cepivo Menitorix prejele sočasno (v drugo stegno) s cepivom DTPa-HBV-IPV.
This powder is dissolved in the solvent provided, just before injection. 
Prašek je treba raztopiti v vehiklu neposredno pred cepljenjem.
Trometamol Sucrose 
Prašek: trometamol saharoza
Haemophilus type b polysaccharide (polyribosylribitol phosphate) 
Polisaharid hemofilusa influence tipa b (poliribozilribitol fosfat)
Also, Menitorix can only protect against meningitis and other infections caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC). 
Cepivo Menitorix lahko ščiti le pred meningitisom in drugimi boleznimi, ki jih povzročata Haemophilus influenzae tipa b (Hib) in Neisseria meningitidis skupine C (MenC).
In three clinical trials (N=209), 92.3% of subjects had an SBA-MenC titre ≥ 1/8 at 11-18 months of age, i.e. at 7-14 months following completion of a 3-dose primary series with Menitorix. 
V treh kliničnih preskušanjih (N = 209) je v starosti od 11 do 18 mesecev, to je od 7 do 14 mesecev po dokončanem osnovnem cepljenju s tremi odmerki cepiva Menitorix, 92,3 % oseb imelo titre SBAMenC ≥ 1/8.
10 vials: Powder 10 pre-filled syringes: Solvent 20 Needles 
10 napolnjenih injekcijskih brizg: vehikel 20 injekcijskih igel
OTHER 
Protitelo
Gastrointestinal disorders: very common: appetite lost uncommon: diarrhoea, vomiting 
Zelo pogosti: izguba apetita Občasni: driska, bruhanje
Neisseria meningitidis serogroup C (strain C11) polysaccharide 
Polisaharid Neisseria meningitidis serološke skupine C (sev C11)
Menitorix can be used to boost toddlers primed with this vaccine or with other licensed Hib and MenC conjugate vaccines. 
Zdravilo Menitorix se lahko uporablja kot poživitveno cepivo pri majhnih otrocih, ki so bili deležni osnovnega cepljenja s tem zdravilom ali z drugimi konjugiranimi cepivi proti Hib in MenC.
Menitorix should under no circumstances be administered intravascularly, intradermally or subcutaneously. 
Cepiva Menitorix se v nobenem primeru ne sme injicirati v žilo, v kožo ali pod kožo.
You should tell your doctor if you notice similar symptoms in your child after vaccination. 
Če po cepljenju pri otroku opazite enake simptome, morate to povedati otrokovemu zdravniku.
Your child can still be given Menitorix if your doctor or nurse advises it but your child may not develop as good protection against Hib and MenC infections as other children. 
Če otrokov zdravnik ali medicinska sestra cepljenje svetuje, lahko otrok cepivo Menitorix kljub temu prejme, vendar pa je zaščita proti Hib in MenC lahko slabša kot pri drugih otrocih.
• Sleepiness 
• Driska.
Some other side effects have been reported very rarely (in less than 1 per 10,000 doses of vaccine) in children who have received other MenC containing vaccines. 
Pri otrocih, ki so bili cepljeni z drugimi cepivi s komponento proti MenC, so zelo redko (pri manj kot 1 od 10.000 odmerkov cepiva) poročali tudi o nekaterih drugih neželenih učinkih.
Powder: trometamol, sucrose 
Prašek: trometamol in saharoza.
10 vials: Powder 10 pre-filled syringes: Solvent 10 x 1 dose (0.5 ml) 
10 napolnjenih injekcijskih brizg: vehikel 10 x 1 odmerek (0,5 ml)
• Haemophilus influenzae type b (Hib): Hib bacteria most frequently cause meningitis (inflammation of the coverings of the brain and spinal cord). 
• Haemophilus influenzae tipa b (Hib): Hib je bakterija, ki najpogosteje povzroči meningitis (vnetje možganskih ovojnic in ovojnic hrbtnega mozga), ki je kljub ozdravitvi lahko povezan z zapleti, kot so duševna zaostalost, spastična paraliza, gluhost ali epilepsija.
Subjects primed with 3 doses of Menitorix* N= 349 
Osebe, ki so bile osnovno cepljenje s 3 odmerki cepiva Menitorix* N = 349
What Menitorix looks like and contents of the pack Menitorix is supplied as a white powder of Hib-MenC vaccine in a glass vial, together with half a millilitre (0.5 ml) of clear colourless sodium chloride solvent in a pre-filled syringe for a 1 dose vaccine. 
En odmerek cepiva Menitorix je na voljo v obliki belega praška (Hib-MenC sestavina cepiva) v stekleni viali in napolnjeni injekcijski brizgi, ki kot vehikel vsebuje pol mililitra (0,5 ml) bistre in brezbarvne raztopine natrijevega klorida.
Anti-PRP antibodies micrograms/ml micrograms/ml GMC (micrograms/ml) 
Anti-PRP protitelesa mikrogramov/ml ≥ 1 mikrogram/ml GMC (mikrogrami/ml)
STATEMENT OF ACTIVE SUBSTANCE(S) After reconstitution, 1 dose (0.5 ml) contains: Haemophilus type b polysaccharide (polyribosylribitol phosphate) 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Po rekonstituciji en odmerek (0,5 ml) cepiva vsebuje: Polisaharid hemofilusa influence tipa b (poliribozilribitol fosfat)
General disorders and administration site conditions: very common: fever (rectal ≥ 38°C), swelling, pain, rednesscommon: injection site reaction uncommon:fever (rectal > 39.5°C), malaise 
Zelo pogosti: zvišana telesna temperatura (rektalna ≥ 38 °C), oteklina, bolečina, rdečina Pogosti: reakcija na mestu injiciranja
Booster vaccination 
Obnovitveno cepljenje
Haemophilus type b and Meningococcal group C conjugate vaccine 
cepivo proti hemofilusu influence tipa b in proti meningokokom vrste C, konjugirano
Subjects primed with 3 doses of Meningitec** or Menjugate** N=96 
Osebe, ki so bile osnovno cepljene s 3 odmerki cepiva Meningitec** ali Menjugate** N = 96
Subjects primed with 3 doses of Menitorix* N=123 
Osebe, ki so bile osnovno cepljenje s 3 odmerki cepiva Menitorix* N = 123
Menitorix will only confer protection against Haemophilus influenzae type b and Neisseria meningitidis group C. As for any vaccine, Menitorix may not completely protect against the infections it is intended to prevent in every vaccinated individual There are no data available on administration of Menitorix in toddlers not already primed with Hib and MenC conjugates. 
Cepivo Menitorix lahko ščiti le pred boleznimi, ki jih povzročata Haemophilus influenzae tipa b in Neisseria meningitidis skupine C. Kot druga cepiva tudi cepivo Menitorix morda ne bo popolnoma zaščitilo vseh cepljenih oseb.
Active immunization of infants from the age of 2 months and toddlers up to the age of 2 years for the prevention of invasive diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis group C (MenC). 
Aktivna imunizacija otrok, starih od 2 mesecev do 2 let, za preprečevanje invazivnih bolezni, ki jih povzročata Haemophilus influenzae tipa b (Hib) in Neisseria meningitidis skupine C (MenC).
Menitorix is not recommended for use in children above 2 years of age due to a lack of data on safety and efficacy. 
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti cepljenje s cepivom Menitorix pri otrocih, starejših od 2 let, ni priporočljivo.